Steroid Dosing for Pediatric Fulminant Idiopathic Intracranial Hypertension (IIH)

First-Line Corticosteroid Treatment Options

The American Academy of Pediatrics recommends prednisone at 2-4 mg/kg/day (maximum 120 mg daily) for 5-7 days as the preferred corticosteroid treatment for pediatric patients with fulminant IIH 1, 2
After initial treatment period, gradual tapering over several months is typically required, as recommended by the American Academy of Pediatrics 3
Prednisone has a more favorable side effect profile compared to dexamethasone for pediatric patients with non-life-threatening conditions, according to the American Academy of Pediatrics 1

The American Academy of Pediatrics suggests that prednisone is better tolerated by pediatric patients regarding short-term side effects 1, 2
Prednisone has a lower risk of severe adverse effects compared to dexamethasone, as reported by the American Academy of Pediatrics 3
The American Academy of Pediatrics notes that prednisone has a more established safety profile in pediatric populations 3, 4

The American Academy of Pediatrics recommends monitoring for growth deceleration (temporary) in pediatric patients taking corticosteroids 3, 5
Weight gain and increased appetite are common side effects of corticosteroid treatment in pediatric patients, according to the American Academy of Pediatrics 3
The American Academy of Pediatrics suggests that hypertension (dose-dependent) is a potential side effect of corticosteroid treatment in pediatric patients 5
Gastric irritation (21-32% of patients) and behavioral changes including irritability, fussiness, and insomnia (up to 29% of patients) are common side effects of corticosteroid treatment in pediatric patients, as reported by the American Academy of Pediatrics 5, 6

The initial high-dose treatment for 5-7 days (prednisone) or 4 days (dexamethasone) is recommended by the American Academy of Pediatrics, followed by gradual tapering over several months based on clinical response 1, 2, 3
Rebound symptoms occur in 14-37% of cases during dose tapering, according to the American Academy of Pediatrics, and may require resumption of steroid therapy if significant rebound occurs 3
The American Academy of Pediatrics notes that increased risk of infection during treatment, reduced B and T-lymphocyte counts, and poor response to vaccines during treatment period are potential concerns with corticosteroid therapy 5, 6